SCHEMBL10255201

SCHEMBL10255201

Cc1cccc(C)c1OCC(C)NC(=O)[C@@H](N)CCO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN4A P35499 10/20 0.54
SCN9A Q15858 5/20 0.54
SCN5A Q14524 3/20 0.54
LMNA P02545 2/20 0.54
SCN1A P35498 2/20 0.54
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2D6 P10635 2/20 0.54
NFKB1 P19838 2/20 0.54
TSHR P16473 2/20 0.54
CYP2C9 P11712 1/20 0.54
KCNK3 O14649 1/20 0.54
CACNA1F O60840 1/20 0.54
KCNK2 O95069 1/20 0.54
GBA1 P04062 1/20 0.54
MAOA P21397 1/20 0.54
HTR2A P28223 1/20 0.54
SLC6A4 P31645 1/20 0.54
HTR2B P41595 1/20 0.54
SCN7A Q01118 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12902791 0.88 SCN4A (0.48) SCN4ASCN9ASCN5ALMNASCN1A
SCHEMBL12902821 0.88 DPP4 (0.49) SCN4ASCN9ASCN5ALMNASCN1A
SCHEMBL27880429 0.88 DPP4 (0.49) SCN4ASCN9ASCN5ALMNASCN1A
SCHEMBL10258215 0.88 SCN4A (0.48) SCN4ASCN9ASCN5ALMNASCN1A
SCHEMBL11953235 0.88 DPP4 (0.49) SCN4ASCN9ASCN5ALMNASCN1A
SCHEMBL11965183 0.86 SCN4A (0.47) SCN4ASCN9ASCN5ALMNASCN1A
SCHEMBL11953239 0.86 SCN4A (0.47) SCN4ASCN9ASCN5ALMNASCN1A
Hydrochloric Acid SCHEMBL6525283 0.86 LMNA (0.49) SCN4ASCN9ASCN5ALMNASCN1A
SCHEMBL11953261 0.86 SCN4A (0.47) SCN4ASCN9ASCN5ALMNASCN1A
Hydrochloric Acid SCHEMBL6525286 0.86 LMNA (0.49) SCN4ASCN9ASCN5ALMNASCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196933-A1 MEXILETINE PRODRUGS FRANKLIN RICHARD (GB) 2012-08-02 US disclosed
US-20120196933-A1 MEXILETINE PRODRUGS FRANKLIN RICHARD (GB) 2012-08-02 US disclosed
WO-2012085586-A1 MEXILETINE PRODRUGS SHIRE, LLC (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196933-A1 MEXILETINE PRODRUGS SLC16A1, MTPN, SLC16A3 SCN4A 88/4885SCN9A 292/4885SCN5A 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.